| Literature DB >> 25267502 |
Tesfaye H Leta1, Stein Håkon L Lygre, Arne Skredderstuen, Geir Hallan, Ove Furnes.
Abstract
BACKGROUND ANDEntities:
Mesh:
Year: 2014 PMID: 25267502 PMCID: PMC4366664 DOI: 10.3109/17453674.2014.964097
Source DB: PubMed Journal: Acta Orthop ISSN: 1745-3674 Impact factor: 3.717
Figure 1.Description of study population for revision total knee arthroplasties (TKAs) (Norwegian Arthroplasty Register (NAR) 1994–2011).
Breakdown of types of revision operations: revision TKAs and re-revision TKAs. Values are percentages
| Type of operation | Revision | Re-revision |
|---|---|---|
| Exchange of femoral or tibial component | 31 | 14 |
| Exchange of the whole prosthesis | 37 | 36 |
| Exchange or insertion of patellar component | 4 | 3 |
| Exchange of tibial liner | 25 | 20 |
| Removal of part of prosthesis | 1 | 18 |
| Other, or incomplete information | 2 | 9 |
Reasons for revision and re-revision TKA operations reported to the NAR from January 1994 through December 2011
| Reason for revision | Revision | Re-revision |
|---|---|---|
| Loose femur | 143 (14) | 13 (9) |
| Loose tibia | 398 (39) | 25 (17) |
| Loose patella | 15 (2) | 2 (1) |
| Dislocation of patella | 28 (3) | 6 (4) |
| Dislocation other than patella | 31 (3) | 6 (4) |
| Instability | 248 (24) | 37 (26) |
| Malalignment | 133 (13) | 10 (7) |
| Deep infection | – | 41 (28) |
| Periprosthetic fracture | 58 (6) | 7 (5) |
| Defect/wear of polyethylene insert | 117 (12) | 6 (4) |
| Pain alone | 83 (8) | 15 (10) |
| Progression of arthritis | 3 (<1) | 1 (1) |
| Arthrofibrosis and stiff knee | 58 (6) | 4 (3) |
| Other, or incomplete information | 46 (5) | 3 (2) |
More than one reason may have been reported.
Excluded from analysis of revision TKAs (see Figure 1).
Figure 2.Survival curve (Kaplan-Meier) for revision TKAs: overall survival of prostheses (panel A), according to year of revision operations (B), according to type of revision TKA (C), and according to type of revision operation (D) with all causes of re-revision as the endpoint.
Kaplan-Meier estimated 5-, 10-, and 15-year survival percentage and median follow-up of revision TKAs with all cases of re-revision as the endpoint (NAR 1994–2011)
| No. of re-revisions /revisions | Median follow-up time in years (95% CI) | % Survival (95% CI) | ||
|---|---|---|---|---|
| 5-year | 10-year | 15-year | ||
| 145 / 1,016 | 4.5 (4.2–4.9) | 85 (82–87) | 78 (75–82) | 71 (62–80) |
Cox relative re-revision risk estimated with all cases of re-revision as the endpoint
| Variables | Re-revision / Revision (n) | RR (95%CI) | p- value | |
|---|---|---|---|---|
| Unadjusted | Adjusted | |||
| Type of revision TKA | ||||
| With non-resurfaced patella | 97 / 744 | Ref. | Ref. | |
| With resurfaced patella | 48 / 272 | 1.0 (0.7–1.5) | 1.0 (0.7–1.5) | 1.0 |
| Sex | ||||
| Female | 78 / 693 | Ref. | Ref. | |
| Male | 67 / 323 | 2.2 (1.6–3.0) | 2.0 (1.4–2.8) | < 0.001 |
| Age at revision | ||||
| > 70 years | 51 / 477 | Ref. | Ref. | |
| 60–70 years | 43 / 284 | 1.4 (1.0–2.2) | 1.3 (0.8–2.0) | 0.2 |
| < 60 years | 51 / 255 | 1.8 (1.3–2.7) | 1.6 (1.1–2.5) | 0.03 |
| Type of fixation | ||||
| Cemented | 128 / 870 | Ref. | Ref. | |
| Hybrid | 15 / 132 | 0.8 (0.5–1.3) | 0.7 (0.4–1.2) | 0.2 |
| Uncemented | 2 / 14 | 1.1 (0.3–4.5) | 1.0 (0.2–4.0) | 1.0 |
| Bone impaction | ||||
| With | 4 / 113 | Ref. | ||
| Without | 54 / 481 | 3.6 (1.3–10.1) |
| 0.01 |
| Stems | ||||
| With | 54 / 427 | Ref. | ||
| Without | 16 / 91 | 1.2 (0.7–2.0) |
| 0.6 |
| PCS | ||||
| With | 45 / 310 | Ref. | ||
| Without | 100 / 706 | 1.1 (0.8–1.5) |
| 0.5 |
| Year of revision operation | ||||
| 2003–2011 | 90 / 787 | Ref. | Ref. | |
| 1994–2002 | 55 / 229 | 1.2 (0.9–1.8) | 1.2 (0.8–1.9) | 0.4 |
| Type of primary TKA | ||||
| With non-resurfaced patella | 113 / 813 | Ref. | Ref. | |
| With resurfaced patella | 32 / 203 | 0.8 (0.6–1.2) | 0.7 (0.5–1.2) | 0.2 |
| Exchange of | ||||
| the whole prosthesis | 35 / 380 | Ref. | Ref. | |
| femoral or tibial component | 54 / 313 | 1.7 (1.1–2.6) | 1.7 (1.1–2.6) | 0.02 |
| tibial liner | 43 / 253 | 1.8 (1.1–2.8) | 1.5 (0.9–2.3) | 0.1 |
p-values for the last reported relative risk (RR).
Adjusted for type of revision TKA, age at revision, sex, type of fixation, year of revision operation, type of primary TKA, type of revision operation, and prosthesis brand in the multiple Cox regression model.
Antibiotic-containing cement was used in 99.9% of cemented prostheses.
Registration of information on the use of bone impaction started in the NAR in 2005. Thus, bone impaction was excluded from the multiple Cox regression model, but sub-analysis was done for revision TKAs performed in 2005 and later. The risk of re-revision of TKAs without bone impaction was 3.2 (95% CI: 1.1–8.9; p = 0.03) compared to those with bone impaction. 52 knees had missing data regarding bone impaction.
We did not adjust for stems due to the high percentage of missing data (30%).
The adjusted risk of re-revision of TKAs without PCS was 1.2 (95% CI: 0.8–1.7; p = 0.4) compared to those with PCS. Adjustment was made for type of revision TKA, age at revision, sex, type of fixation, year of revision operation, type of primary TKA, and prosthesis brand in the multiple Cox regression model.
Due to the small group size, and to achieve more homogeneity, prostheses with type of revision operation other than exchange of the whole prosthesis, exchange of the femoral or tibial component alone, and exchange of the tibial liner were excluded from the Cox regression analyses.
Figure 3.Survival curve (Kaplan-Meier) for revision TKAs according to type of fixation (panel A), bone impaction (B), stem (C), and posterior cruciate stabilization (D). Registration of information about the use of bone impaction started in 2005. Thus, survival analysis according to bone impaction was done only for revision TKA operations reported to the NAR in 2005 and later.
Figure 4.Survival curve (Kaplan-Meier) according to the brand of revision prosthesis reported to the NAR 1994–2011 (n ≥ 50).
Demographic data for 1,016 revision TKAs reported to the NAR from January 1994 to December 2011. Values are percentages
| Age at revision | Males | Type of fixation | Stems | Bone impaction | PCS | TKA–NRP | Revised 2003–2011 | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| < 60 | 60–70 | > 70 | Cemented | Hybrid | Uncemented | ||||||
| 25 | 28 | 47 | 32 | 86 | 13 | 1 | 42 | 18 | 30 | 73 | 78 |
30% of revision TKAs had missing information regarding stems.
Registration of information about the use of bone impaction started in 2005. Thus, this is the percentage of those knees operated between 2005 and 2011.
PCS: posterior cruciate stabilizing.
TKA–NRP: revision total knee arthroplasty with non-resurfaced patella.
Antibiotic-loaded bone cement was used in 99.9% of cemented prostheses.
Some, but not all components (femoral, tibial, or patellar) were cemented.
Demographic data on prosthesis brands commonly used in revision TKA operations reported to the NAR from January 1994 through December 2011
| Brand of prosthesis | No. of prostheses | Age at revision | No. of males | No. of hospitals | No. of TKA–NRP | ||
|---|---|---|---|---|---|---|---|
| < 60 | 60–70 | > 70 | |||||
| Profix | 255 | 82 | 81 | 92 | 74 | 44 | 185 |
| LCS Complete | 212 | 41 | 70 | 101 | 72 | 33 | 196 |
| LCS | 150 | 23 | 43 | 84 | 38 | 29 | 110 |
| Genesis I | 122 | 24 | 24 | 74 | 37 | 20 | 63 |
| NexGen | 79 | 28 | 20 | 31 | 26 | 26 | 48 |
| Duracon | 74 | 26 | 21 | 27 | 31 | 13 | 61 |
| Vanguard | 28 | 3 | 9 | 16 | 8 | 8 | 27 |
| Triathlon | 20 | 3 | 4 | 13 | 8 | 13 | 20 |
| AGC Anatomic | 19 | 8 | 2 | 9 | 8 | 10 | 8 |
| Kinemax | 16 | 0 | 3 | 13 | 4 | 7 | 4 |
| AGC Universal | 16 | 7 | 3 | 6 | 7 | 8 | 9 |
| Tricon II | 15 | 7 | 2 | 6 | 6 | 11 | 5 |
| MAXIM | 10 | 3 | 2 | 5 | 4 | 5 | 8 |
| Total | 1,016 | 255 | 284 | 477 | 323 | 66 | 744 |
Number of hospitals that had used each of these prosthesis brands for revision.
Revision total knee arthroplasty with non-resurfaced patella.
Mobile-bearing prosthesis brands.
42 LCS for femoral component, 2 LCS for intermediate component, 2 LCS, 1 Profix, and 1 LCS Universal for distal component were used in combination with LCS Complete for femoral component.
3 LCS Universal for distal component, 121 LCS Universal for intermediate component, 1 LCS Complete for intermediate component, and 2 LCS Complete for patellar component were used in combination with LCS.
1 Tricon II for distal component, 1 Tricon II for intermediate component, and 1 Tricon-C with Pro-Fit for femoral component were used in combination with Genesis I.
1 KOTZ femoral and 1 KOTZ distal were used in combination with Duracon for other components.
1 AGC Universal for patellar component was used in combination with Vanguard for other component.
3 MAXIM for distal component and 4 MAXIM for intermediate component were used in combination with AGC Anatomic for femoral component.
12 Tricon-C with Pro-Fit for femoral component and 3 Tricon-M for femoral component were used in combination with Tricon II.
10 AGC Anatomic for femoral component and 3 AGC Anatomic for patellar component were used in combination with MAXIM for other components.
Total number of hospitals that had reported revision TKA operations to the NAR between 1994 and 2011.